Vilacto Bio (VIBI) 10-Q 14 Feb 18 2017 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Dec. 31, 2017	Feb. 13, 2018
Document And Entity Information
Entity Registrant Name	Vilacto Bio Inc.
Entity Central Index Key	1,576,724
Document Type	10-Q
Document Period End Date	Dec. 31, 2017
Amendment Flag	false
Current Fiscal Year End Date	--03-31
Is Entity a Well-known Seasoned Issuer?	No
Is Entity a Voluntary Filer?	No
Is Entity's Reporting Status Current?	Yes
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		90,000,000
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2,017

Balance Sheets

Balance Sheets - USD ($)	Dec. 31, 2017	Mar. 31, 2017
Current assets
Cash	$ 7,319	$ 22,020
Accounts receivable	70
Inventory	133,876
Prepaid expenses	65,000	225
Total current assets	206,265	22,245
Intangible assets, net	911
Total assets	207,176	22,245
Current liabilities
Accounts payable and accrued liabilities	24,453	9,223
Due to related parties	252,249	711
Loans	174,000	22,500
Loans from related parties	32,608	32,608
Total current liabilities	483,310	65,042
Total liabilities	483,310	65,042
Common stock; $0.001 par value; 1,125,000,000 shares authorized; 90,000,000 and 90,000,000 shares issued and outstanding as of December 31, 2017 and March 31, 2017, respectively	90,000	90,000
Additional paid-in capital	(22,000)	(22,000)
Accumulated earnings (deficit)	(344,134)	(110,797)
Total stockholders' equity (deficit)	(276,134)	(42,797)
Total liabilities and stockholders' equity (deficit)	$ 207,176	$ 22,245

Balance Sheets (Parenthetical)

Balance Sheets (Parenthetical) - $ / shares	Dec. 31, 2017	Mar. 31, 2017
Stockholders' equity
Common stock, par value	$ 0.001	$ 0.001
Common stock shares, authorized	1,125,000,000	1,125,000,000
Common stock shares, issued	90,000,000	90,000,000
Common stock shares, outstanding	90,000,000	90,000,000

Statements of Operations

Statements of Operations - USD ($)	3 Months Ended		9 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2017	Dec. 31, 2016
Income Statement [Abstract]
Revenues	$ 322		$ 322
Cost of revenues	103		103
Gross profit	219		219
Operating expenses
Royalty expense	30,000		90,000
Professional fees	22,247	1,765	57,029	7,595
General and administrative expenses	46,784	1,002	81,037	3,169
Depreciation expense	9		9
Total operating expenses	99,040	2,767	228,075	10,764
Loss from operations	(98,821)	(2,767)	(227,856)	(10,764)
Other income (expense)
Interest expense	(2,625)		(5,481)
Total other income (expense)	2,625		5,481
Net income (loss)	$ (101,446)	$ (2,767)	$ (233,337)	$ (10,764)
Basic income (loss) per common share	$ 0	$ 0	$ 0	$ 0
Basic weighted average common shares outstanding	90,000,000	90,000,000	90,000,000	90,000,000

Statements of Cash Flows

Statements of Cash Flows - USD ($)	9 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Cash Flows from Operating Activities
Net loss	$ (233,337)	$ (10,764)
Adjustments to reconcile net loss to net cash provided by operating activities:
Contributed capital
Depreciation and amortization	9
Changes in assets and liabilities
Increase (decrease) in accounts receivable	(70)
(Increase) decrease in prepaid expense	(64,775)	(106)
(Increase) decrease in inventory	(133,876)
Increase (decrease) in accounts payable	211,379	(200)
Net cash from operating activities	(220,670)	(11,070)
Cash Flows from investing
Purchase of intangible assets	920
Net cash used in investing activities	(920)
Cash Flows from Financing Activities
Proceeds from promissory notes	151,500
Advance from related parties	55,389	11,022
Net cash from financing activities	206,889	11,022
Net increase (decrease) in Cash	(14,701)	(48)
Beginning cash balance	22,020	482
Ending cash balance	7,319	434
Supplemental disclosure of cash flow information
Cash paid for interest
Cash paid for tax

Organization and Line Business

Organization and Line Business	9 Months Ended
	Dec. 31, 2017
Notes to Financial Statements
NOTE 1 - ORGANIZATION AND LINE BUSINESS	The Company was originally incorporated under the laws of the state of Nevada on February 25, 2013. The Company is devoting substantially all of its present efforts to establish a new business, and has had no revenues from operations to date. On April 4, 2017, the Company entered into a license agreement (the “License Agreement”) with Pharma GP ApS. (“Pharma GP”) and acquired an exclusive license to sell certain cosmetic products or ingredients covered by United States Patent No. US 8,637,075 in the territory of the United States. As a result of the License Agreement, the Company is currently marketing a line of skin care products on its website at www.vilacto.com. These products include, lotions, skin care creams and gels, lip balms, foot creams and oils, and similar items. The Company also entered into a Stock Purchase Agreement (the “Purchase Agreement”) with Pharma GP and its sole shareholder, 9 Heroes APS, a Denmark corporation (together, “Seller”). In accordance with the terms of the Purchase Agreement, the Company agreed to purchase all of the outstanding shares of Pharma GP for the purchase price (the “Purchase Price”) of $6,000,000, payable as $3,000,000 in cash and the balance in shares of our common stock. The closing of the above transactions was expected to occur by May 31, 2017, but will likely not occur until the Company is able to successfully raise capital for the Purchase Price.

Basis of Presentation and Going

Basis of Presentation and Going Concern	9 Months Ended
	Dec. 31, 2017
Notes to Financial Statements
NOTE 2. BASIS OF PRESENTATION AND GOING CONCERN	The accompanying unaudited interim financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States of America and the rules of the Securities and Exchange Commission, and should be read in conjunction with the audited financial statements and notes thereto contained in the Company’s most recent Annual Financial Statements filed with the SEC on Form 10-K. In the opinion of management, all adjustments, consisting of normal recurring adjustments, necessary for a fair presentation of financial position and the results of operations for the interim period presented have been reflected herein. The results of operations for the interim period are not necessarily indicative of the results to be expected for the full year. Notes to the financial statements which would substantially duplicate the disclosures contained in the audited financial statements for the most recent fiscal period, as reported in the Form 10-K, have been omitted. Going concern

Summary of Significant Policies

Summary of Significant Policies	9 Months Ended
	Dec. 31, 2017
Notes to Financial Statements
NOTE 3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	This summary of significant accounting policies of Vilacto Bio Inc. is presented to assist in understanding the Company’s financial statements. The financial statements and notes are representations of the Company’s management, who are responsible for their integrity and objectivity. These accounting policies conform to accounting principles generally accepted in the United States of America, and have been consistently applied in the preparation of the financial statements. Use of estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant estimates include estimates used to review the Company’s goodwill, impairments and estimations of long-lived assets, revenue recognition on percentage of completion type contracts, allowances for uncollectible accounts, inventory valuation, and the valuations of non-cash capital stock issuances. The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable in the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions. Revenue Recognition Accounts Receivable Cash and cash equivalents Concentration Risk At times throughout the year, the Company may maintain cash balances in certain bank accounts in excess of FDIC limits. As of December 31, 2017, the cash balance in excess of the FDIC limits was $0. The Company has not experienced any losses in such accounts and believes it is not exposed to any significant credit risk in these accounts. Fair Value of Financial Instruments As required by the Fair Value Measurements and Disclosures Topic of the FASB ASC, fair value is measured based on a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows: (Level 1) observable inputs such as quoted prices in active markets; (Level 2) inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; and (Level 3) unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions. The three levels of the fair value hierarchy are described below: Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities; Level 2: Quoted prices in markets that are not active, or inputs that are observable, either directly or indirectly, for substantially the full term of the asset or liability; Level 3: Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (supported by little or no market activity). Stock-based compensation Compensation-Stock Compensation, Non-Employee Stock Based Compensation Earnings (loss) per share Earnings Per Share, Long-lived Assets Indefinite Lived Intangibles and Goodwill Assets The Company accounts for business combinations under the acquisition method of accounting in accordance with ASC 805, “Business Combinations,” where the total purchase price is allocated to the tangible and identified intangible assets acquired and liabilities assumed based on their estimated fair values. The purchase price is allocated using the information currently available, and may be adjusted, up to one year from acquisition date, after obtaining more information regarding, among other things, asset valuations, liabilities assumed and revisions to preliminary estimates. The purchase price in excess of the fair value of the tangible and identified intangible assets acquired less liabilities assumed is recognized as goodwill. The Company tests for indefinite lived intangibles and goodwill impairment in the fourth quarter of each year and whenever events or circumstances indicate that the carrying amount of the asset exceeds its fair value and may not be recoverable. In accordance with its policies, the Company performed a qualitative assessment of indefinite lived intangibles and goodwill at December 31, 2017, and determined there was no impairment of indefinite lived intangibles and goodwill. Business Combinations The Company allocates the fair value of purchase consideration to the tangible assets acquired, liabilities assumed and intangible assets acquired based on their estimated fair values. The excess of the fair value of purchase consideration over the fair values of these identifiable assets and liabilities is recorded as goodwill. Such valuations require management to make significant estimates and assumptions, especially with respect to intangible assets. Significant estimates in valuing certain intangible assets include, but are not limited to, future expected cash flows from acquired customer lists, acquired technology, and trade names from a market participant perspective, useful lives and discount rates. Management’s estimates of fair value are based upon assumptions believed to be reasonable, but which are inherently uncertain and unpredictable and, as a result, actual results may differ from estimates. During the measurement period, which is one year from the acquisition date, the Company may record adjustments to the assets acquired and liabilities assumed, with the corresponding offset to goodwill. Upon the conclusion of the measurement period, any subsequent adjustments are recorded to earnings. Inventory Income taxes Income Taxes Segment Reporting Recently Issued Accounting Pronouncements

Inventory

Inventory	9 Months Ended
	Dec. 31, 2017
Inventory Disclosure [Abstract]
NOTE 4. INVENTORY	Inventory consist of the following as of December 31, 2017 and March 31, 2017: December 31, 2017 March 31, 2017 Raw materials $ — $ — Finished Goods 133,876 — Total $ 133,876 $ —

Loans Payable

Loans Payable	9 Months Ended
	Dec. 31, 2017
Receivables [Abstract]
NOTE 5. LOANS PAYABLE	On March 5, 2017, the Company executed a $22,500 promissory note with an investor which bears interest at a rate of 5% per annum and is due within two business days of demand notice. During the nine months ending December 31, 2017 the Company recorded interest of $848. On May 17, 2017, the Company executed a $22,500 promissory note with an investor which bears interest at a rate of 5% per annum and is due within two business days of demand notice. During the nine months ending December 31, 2017 the Company recorded interest of $703. On July 5, 2017, the Company executed a $20,000 promissory note with an investor which bears interest at a rate of 5% per annum and is due within two business days of demand notice. During the nine months ending December 31, 2017 the Company recorded interest of $490. On October 4, 2017, the Company executed a $65,000 promissory note with an investor which bears interest at a rate of 5% per annum and is due within two business days of demand notice. During the nine months ending December 31, 2017 the Company recorded interest of $784. On November 28, 2017, the Company executed a $44,000 promissory note with an investor which bears interest at a rate of 5% per annum and is due within two business days of demand notice. During the nine months ending December 31, 2017 the Company recorded interest of $199.

Stockholders' Equity

Stockholders' Equity	9 Months Ended
	Dec. 31, 2017
Notes to Financial Statements
NOTE 6. STOCKHOLDERS' EQUITY	On March 6, 2017, our board of directors resolved to increase the number of authorized shares of our common stock, par value $0.001, from 75,000,000 shares to 1,125,000,000 shares. Correspondingly, our board of directors affirmed a forward split of 15 for 1 in which each shareholder will be issued 15 common shares in exchange for 1 common share of their currently issued common stock. In accordance with ASC 505-20 all stock-related information presented in these financial statements and accompanying footnotes has been retroactively adjusted to reflect the number of shares resulting from this action. Prior to approval of the forward split, we had a total of 6,000,000 issued and outstanding common shares, par value $0.001. On the effective date of the forward split, we had a total of 90,000,000 issued and outstanding common shares, par value $0.001. Overview The Company is authorized to issue 1,125,000,000 shares of $0.001 par value common stock. All common stock shares have equal voting rights, are non-assessable and have one vote per share. Voting rights are not cumulative and, therefore, the holders of more than 50% of the common stock could, if they choose to do so, elect all of the directors of the Company. As of December 31, 2017, there were 90,000,000 shares of common stock issued and outstanding. Stock purchase agreement On April 19, 2017, we entered into a Stock Purchase Agreement (the “Agreement”) with Pharma GP APS, a Denmark corporation (“Pharma GP”) and its sole shareholder, 9 Heroes APS, a Denmark corporation. In accordance with the terms of the Agreement, we agreed to purchase all of the outstanding shares of Pharma GP for the purchase price (the “Purchase Price”) of $6,000,000.00, payable as $3,000,000.00 in cash and the balance in shares of our common stock. The closing of the above transactions is expected to occur when the company has sufficient funds to do so. The Agreement is conditioned on our paying the Purchase Price, obtaining financing in the amount of $4,000,000.00 for operational expenses, and receiving audited financial statements from Pharma GP, among other conditions as contained in the Agreement. We currently do not have the money on hand to pay the Purchase Price, and we must obtain additional financing to meet the conditions to close the transaction. The Agreement includes customary representations, warranties and covenants among the parties to each other as of specific dates. The foregoing description of the Agreement is qualified in its entirety by reference to the full text of the Agreement, which is included as an exhibit our Current Report on Form 8-K filed on April 20, 2017 and is incorporated by reference herein. Pharma GP is a manufacturer of skincare products with distribution in several countries. The company’s body and facial creams are designed for moisturizing, skin regeneration, wound healing and a variety of skin issues, such as dry and cracked skin, among other things. In addition, Pharma GP owns patents, trademarks and production facilities for an ingredient designed to be used in pharmaceuticals and medical devices for treating a wide range of issues. Pharma GP currently has skincare products that are available over the counter. However, the company intends to develop, market and sell pharmaceutical skincare products to treat various ailments using its patented technology. Currently, the company has no government approved products, but with the financing, we intend to purchase Pharma GP and focus on those clinical applications. We expect to have more information on the status of the Closing of the Agreement and our new business direction in future filings.

Related Party Transactions

Related Party Transactions	9 Months Ended
	Dec. 31, 2017
Notes to Financial Statements
NOTE 7. RELATED PARTY TRANSACTIONS	On February 21, 2017, Dana Gallovicova, our former CEO agreed to transfer her 75,000,000 shares of common stock in the Company to Gert Andersen pursuant to a Stock Purchase Agreement. Ms. Gallovicova received proceeds of $100,000. The source of the consideration paid to Ms. Gallovicova was the existing funds of the purchaser. Ms. Gallovicova also assigned all of the outstanding debt owed to her by the Company to Mr. Andersen for $32,608. In connection with the debt assignment, Ms. Gallovicova agreed to release the Company from any and all claims. In connection with the assumption of the aforementioned debt the Company executed a promissory note with Mr. Anderson which bears interest at a rate of 10% per annum. During the nine months ending December 31, 2017 the Company recorded interest of $2,457. In connection with the sale of her controlling interest in the company, on February 24, 2017, Ms. Gallovicova appointed Mr. Andersen as our new Director, President, CEO, Secretary and Treasurer and then resigned from all officer and director positions. There were no other arrangements or understandings between Ms. Gallovicova and Mr. Andersen with respect to election of directors or other matters. During the nine months ended December 31, 2017, Gert Anderson, the President and CEO of the Company advanced $55,389 to the Company to pay expenses on behalf of the Company. The advances bear no interest, are unsecured, and due on demand. During the nine months ended December 31, 2017, the Company purchased $134,064 in inventory from Pharma GP APS, which it sells via its online stores.

Royalty Agreement

Royalty Agreement	9 Months Ended
	Dec. 31, 2017
Research and Development [Abstract]
NOTE 8. ROYALTY AGREEMENT	License agreement On April 4, 2017, we entered into a license agreement (the “License Agreement”) with Pharma GP APS. (“Pharma GP”) and acquired an exclusive license to sell certain cosmetic products or ingredients covered by United States Patent No. US 8,637,075 in the territory of the United States. For the license, we agreed to pay to GP a royalty of eight percent (8%) on the selling price (irrespective of any taxes, custom duties, costs of insurance, transportation costs or other costs) for all licensed product we sell in the United States (if in excess of the agreed minimum royalty), or pay the agreed minimum royalty of $10,000 per month. During the nine months ended December 31, 2017, the Company recorded royalty expense of $90,000 related to this agreement. Under the License Agreement, we have the ability to sublicense to third parties under the royalty arrangement described above.

Subsequent Event

Subsequent Event	9 Months Ended
	Dec. 31, 2017
Notes to Financial Statements
NOTE 9. SUBSEQUENT EVENT	The Company has evaluated events subsequent to the balance sheet through the issuance date of these financial statements in accordance with FASB ASC 855 and has determined that there are no such events that would require adjustment to, or disclosure in, the financial statements.

Summary of Significant Polici15

Summary of Significant Policies (Policies)	9 Months Ended
	Dec. 31, 2017
Summary Of Significant Accounting Policies Policies
Accounts Receivable	Accounts Receivable
Basis of Presentation	The financial statements of the Company have been prepared using the accrual basis of accounting in accordance with generally accepted accounting principles in the United States of America and are presented in U.S. dollars. The Company has adopted a March 31 fiscal year end.
Dividends	The Company has not yet adopted any policy regarding payment of dividends. No dividends have been paid during the periods shown.
Cash and Cash Equivalents	Cash and cash equivalents
Earnings per Share	Earnings (loss) per share Earnings Per Share,
Fair Value of Financial Instruments	Fair Value of Financial Instruments As required by the Fair Value Measurements and Disclosures Topic of the FASB ASC, fair value is measured based on a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows: (Level 1) observable inputs such as quoted prices in active markets; (Level 2) inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; and (Level 3) unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions. The three levels of the fair value hierarchy are described below: Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities; Level 2: Quoted prices in markets that are not active, or inputs that are observable, either directly or indirectly, for substantially the full term of the asset or liability; Level 3: Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (supported by little or no market activity).
Income Taxes	Income taxes Income Taxes
Revenue Recognition	Revenue Recognition
Use of Estimates	Use of estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant estimates include estimates used to review the Company’s goodwill, impairments and estimations of long-lived assets, revenue recognition on percentage of completion type contracts, allowances for uncollectible accounts, inventory valuation, and the valuations of non-cash capital stock issuances. The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable in the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.
Recently Issued Accounting Pronouncements	Recently Issued Accounting Pronouncements
Concentration Risk	Concentration Risk At times throughout the year, the Company may maintain cash balances in certain bank accounts in excess of FDIC limits. As of December 31, 2017, the cash balance in excess of the FDIC limits was $0. The Company has not experienced any losses in such accounts and believes it is not exposed to any significant credit risk in these accounts.
Stock Based Compensation	Stock-based compensation Compensation-Stock Compensation,
Non-Employee Stock Based Compensation	Non-Employee Stock Based Compensation
Long Lived Assets	Long-lived Assets
Indefinite Lived Intangibles and Goodwill Assets	Indefinite Lived Intangibles and Goodwill Assets The Company accounts for business combinations under the acquisition method of accounting in accordance with ASC 805, “Business Combinations,” where the total purchase price is allocated to the tangible and identified intangible assets acquired and liabilities assumed based on their estimated fair values. The purchase price is allocated using the information currently available, and may be adjusted, up to one year from acquisition date, after obtaining more information regarding, among other things, asset valuations, liabilities assumed and revisions to preliminary estimates. The purchase price in excess of the fair value of the tangible and identified intangible assets acquired less liabilities assumed is recognized as goodwill. The Company tests for indefinite lived intangibles and goodwill impairment in the fourth quarter of each year and whenever events or circumstances indicate that the carrying amount of the asset exceeds its fair value and may not be recoverable. In accordance with its policies, the Company performed a qualitative assessment of indefinite lived intangibles and goodwill at December 31, 2017, and determined there was no impairment of indefinite lived intangibles and goodwill.
Business Combinations	Business Combinations The Company allocates the fair value of purchase consideration to the tangible assets acquired, liabilities assumed and intangible assets acquired based on their estimated fair values. The excess of the fair value of purchase consideration over the fair values of these identifiable assets and liabilities is recorded as goodwill. Such valuations require management to make significant estimates and assumptions, especially with respect to intangible assets. Significant estimates in valuing certain intangible assets include, but are not limited to, future expected cash flows from acquired customer lists, acquired technology, and trade names from a market participant perspective, useful lives and discount rates. Management’s estimates of fair value are based upon assumptions believed to be reasonable, but which are inherently uncertain and unpredictable and, as a result, actual results may differ from estimates. During the measurement period, which is one year from the acquisition date, the Company may record adjustments to the assets acquired and liabilities assumed, with the corresponding offset to goodwill. Upon the conclusion of the measurement period, any subsequent adjustments are recorded to earnings.
Segment Reporting	Segment Reporting
Inventory	Inventory

Inventory (Tables)

Inventory (Tables)	9 Months Ended
	Dec. 31, 2017
Inventory Disclosure [Abstract]
Inventory	December 31, 2017 March 31, 2017 Raw materials $ — $ — Finished Goods 133,876 — Total $ 133,876 $ —

Organization and Line Business

Organization and Line Business (Details Narrative)	9 Months Ended
	Dec. 31, 2017USD ($)
Notes to Financial Statements
State Country Name	State of Nevada
Date of incorporation	Feb. 25, 2013
Date of license agreement with Pharma GP ApS	Apr. 4, 2017
Purchase price of Pharma GP outstanding shares	$ 6,000,000
Payable in cash	$ 3,000,000

Basis of Presentation and Goi18

Basis of Presentation and Going Concern (Details Narrative) - USD ($)	3 Months Ended		9 Months Ended		52 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2017
Going Concern Details Narrative
Net loss	$ (101,446)	$ (2,767)	$ (233,337)	$ (10,764)	$ 344,134

Summary of Significant Polici19

Summary of Significant Policies (Details Narrative) - USD ($)	9 Months Ended		12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Mar. 31, 2017	Mar. 31, 2016
Accounting Policies [Abstract]
Revenues	322	0
Year end revenues			$ 0	$ 0
Allowance for doubfult accounts	$ 0		0
Cash and Cash Equivalents	7,319		$ 22,020
Cash in excess of FDIC limits	$ 0

Inventory (Details)

Inventory (Details) - USD ($)	Dec. 31, 2017	Mar. 31, 2017
Inventory Disclosure [Abstract]
Raw Materials
Finished Goods	133,876
Total	$ 133,876

Loans Payable (Details Narrativ

Loans Payable (Details Narrative)	9 Months Ended
	Dec. 31, 2017USD ($)	Nov. 28, 2017USD ($)	Oct. 04, 2017USD ($)	Jul. 05, 2017USD ($)	May 17, 2017USD ($)	Mar. 05, 2017USD ($)
Promissorry Note		$ 44,000	$ 65,000	$ 20,000	$ 22,500	$ 22,500
Interest Rate of Promissory Note		.05	.05	0.05	0.05	0.05
Loans Payable 1 [Member]
Interst Recorded	$ 848
Days due within demand notice	2 days
Loans Payable 2 [Member]
Interst Recorded	$ 703
Days due within demand notice	2 days
Loans Payable 3 [Member]
Interst Recorded	$ 490
Days due within demand notice	2 days
Loans Payable 4 [Member]
Interst Recorded	$ 784
Days due within demand notice	2 days
Loans Payable 5 [Member]
Interst Recorded	$ 199
Days due within demand notice	2 days

Stockholders' Equity (Details N

Stockholders' Equity (Details Narrative)	9 Months Ended
	Dec. 31, 2017$ / sharesshares	Apr. 19, 2017USD ($)	Mar. 31, 2017$ / sharesshares
Date of Forward Split	Mar. 6, 2017
Common stock, par value | $ / shares	$ 0.001		$ 0.001
Common Shares Authorized before split	75,000,000
Common stock shares, authorized	1,125,000,000		1,125,000,000
Foward Split shares after | $ / shares	$ 15
Forward Split shares prior | $ / shares	$ 1
Stock Authorized to Issue	1,125,000
Stock Authorized to Issue, Value per share	0.001
Common Stock Issued and Outstanding	90,000,000		90,000,000
Purchase Price of Pharma Agreement | $		$ 6,000,000
Payable in cash of purchase agreement | $		3,000,000
Amount of financing to be obtained for purchase agreement | $		$ 4,000,000
Closing date of purchase agreement	Sep. 30, 2017
Percentage of Shareholders needed to select all directors of Company	50.00%

Related Party Transactions (Det

Related Party Transactions (Details Narrative)	1 Months Ended	9 Months Ended
	Feb. 21, 2017USD ($)shares	Dec. 31, 2017USD ($)
Advances from officer		$ 55,389
Interst of Advance from officer		0
Interest Accrued		$ 2,457
Inventory Purchased from Pharma GP APS		$ 134,064
Former CEO [Member]
Stock Transferred for Services, Shares | shares	75,000,000
Stock Transferred for Services, Amount	$ 100,000
Debt Assigned for Payment	$ 32,608
Promissory Note Interest Rate	0.10

Royalty Agreement (Details Narr

Royalty Agreement (Details Narrative)	3 Months Ended		9 Months Ended
	Dec. 31, 2017USD ($)	Dec. 31, 2016USD ($)	Dec. 31, 2017USD ($)	Dec. 31, 2016USD ($)
Research and Development [Abstract]
Date of License Agreement			Apr. 4, 2017
Royaly Percentage			0.08
Minimum Royalty per month			$ 10,000
Royalty Expense	$ 30,000		$ 90,000